News

Find News

Filter articles

Showing 3051 to 3060 of 3417 results

August newsletter in 60 seconds

04-09-2014

Our expert comment this month looks at personalised medicine, but more from a business point of view than a medical one. As LSIPR readers will know, personalised medicine is all about tailoring treatment to the individual, and that, of course, can be extremely complicated.

Simmons & Simmons hires new partner

Germany03-09-2014

Law firm Simmons & Simmons has expanded its Düsseldorf office with the addition of a new partner.

English High Court invalidates Symbicort patent

UK03-09-2014Legal developments

English High Court Justice Philip James Sales has found a patent covering AstraZeneca’s bestselling drug Symbicort invalid after a challenge by Israeli generic drug maker Teva.

WilmerHale adds Dentons litigator to London team

UK02-09-2014

WilmerHale has added life sciences lawyer and IP litigation specialist Anthony Trenton to its practice in London.

Sandoz barred from making Remodulin generic until 2017

US01-09-2014Legal developments

Novartis’s generic arm Sandoz may not market a generic version of Maryland-based United Therapeutics’ Remodulin hypertension drug, the US District Court for the District of New Jersey ruled on Friday (August 29).

FDA accepts generic applications for three-times-weekly Copaxone

US29-08-2014

The FDA has accepted applications by generic drug makers Mylan and Novartis subsidiary Sandoz for a three-times-weekly version of blockbuster drug Copaxone, it was announced yesterday.

Novartis sues Zydus over Alzheimer and Parkinson’s disease drug

US28-08-2014

Novartis Pharmaceuticals has launched a lawsuit against generics company Zydus Noveltech and its subsidiaries, accusing them of infringing patents relating to a drug used to treat Alzheimer’s and Parkinson’s disease.

Federal Circuit upholds invalidity decision on Humira patent

US22-08-2014Legal developments

The US Court of Appeals for the Federal Circuit yesterday (August 21) upheld a lower court’s decision that a patent covering rheumatoid arthritis drug Humira (adalimumab) is invalid.

New Jersey court blocks Actavis’s generic Gralise

US21-08-2014Legal developments

The US District Court for the District of New Jersey has ruled that Actavis may not launch a generic version of California-based Depomed’s Gralise (gabapentin), it has been announced.

GeneDx claims 11 Myriad patents are invalid

US21-08-2014Legal developments

The molecular diagnostic testing company GeneDx has petitioned the US Patent and Trademark Office to invalidate 11 patents asserted by Myriad in a lawsuit filed against GeneDx in October 2013.

Showing 3051 to 3060 of 3417 results

LSIPR